07:00 , Jul 15, 2013 |  BC Week In Review  |  Company News

Galen, Nuvo sales and marketing update

Nuvo and its Zars Pharma Inc. subsidiary granted Galen's Galen U.S. Inc. subsidiary exclusive, U.S. rights to commercialize Nuvo's Synera patch. The license is for Synera's approved indication - to provide local dermal analgesia for...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Company News

Nuvo, Paladin deal

In March, Nuvo said the Mallinckrodt Inc. subsidiary of Covidien plc (NYSE:COV, Dublin, Ireland) received a complete response letter for an NDA for Pennsaid 2% to treat osteoarthritis (OA) of the knee. FDA requested a...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Nuvo, Paladin deal

Nuvo granted Paladin exclusive rights in Canada to commercialize Synera , a local anesthetic patch marketed in the U.S. to provide local dermal anesthesia for superficial procedures. Nuvo is eligible to receive double-digit royalties on...
07:00 , May 23, 2011 |  BC Week In Review  |  Company News

Nuvo, Zars deal

Nuvo acquired pain company Zars Pharma in a stock deal valued at C$10.5 million ($10.8 million) based on Nuvo's close of C$0.11 the day before the deal closed. Zars shareholders received about 99.8 million Nuvo...
08:00 , Mar 3, 2008 |  BC Week In Review  |  Company News

EUSA, Endo, Zars sales and marketing update

EUSA disclosed that earlier this year it launched Rapydan lidocaine/ tetracaine in Germany, the U.K. and the Netherlands for surface anesthesia of the skin in connection with needle puncture. The anesthetic patch that uses controlled,...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Clinical News

Rapydan regulatory update

EUSA received approval in 18 EU countries under the mutual recognition procedure for Rapydan for surface anesthesia of the skin in connection with needle puncture. The anesthetic patch containing 70 mg lidocaine and 70 mg...
00:15 , Oct 9, 2007 |  BC Extra  |  Financial News

Zars pulls IPO

Zars (Salt Lake City, Utah) withdrew its IPO, citing market conditions. The company filed in June to raise up to $86.3 million in an offering underwritten by Cowen; CIBC; Leerink; and Susquehanna. In August, the...
07:00 , Sep 24, 2007 |  BioCentury  |  Finance

Ebb & Flow

Having chalked up a number of specialty pharma exits over the last few years, Domain Associates made another tidy exit last week, as urology and gynecology company Esprit is being acquired by Allergan (AGN) for...
07:00 , Aug 27, 2007 |  BioCentury  |  Finance

Ebb & Flow

Activist investors enjoyed an immediate pop after PDL BioPharma CEO Mark McDade announced last week that he would resign by year end. The news boosted the shares $2.65 (13%) to $23.81 on the week, while...
00:08 , Aug 25, 2007 |  BC Extra  |  Financial News

Zars amends IPO

Zars (Salt Lake City, Utah) amended its IPO and hopes to sell 5 million shares at $14-$16 in an offering underwritten by Cowen; CIBC World Markets; Leerink; and Susquehanna. A $15 price would raise $75...